• If you are wondering whether Elanco Animal Health at around US$24.71 is priced for further upside or already reflecting high expectations, the valuation picture is where the real story starts.
• The stock has seen strong returns, with gains of 3.0% over 7 days, 7.5% over 30 days, 9.7% year to date and 84.0% over the past year, while the 3 year return is 164.3% and the 5 year return has declined 26.4%.
• Recent coverage has focused on how Elanco Animal Health is repositioning within animal health and pharmaceuticals, with investors reacting to updates around its product pipeline and portfolio focus. These developments give important context to the recent share price performance and set the scene for a closer look at what investors may be pricing in.
• On Simply Wall St's valuation checks, Elanco Animal Health scores 6 out of 6, and the next sections will walk through the key valuation approaches behind that score, with a more complete way to judge value saved for the end of the article.

Approach 1: Elanco Animal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s dollars, aiming to estimate what the business could be worth right now.

For Elanco Animal Health, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow sits at about $355.3 million. Analyst and extrapolated projections in the model see annual free cash flow figures in the mid hundreds of millions, reaching $742.0 million by 2030, with further estimated values extending out to 2035.

Discounting these projected cash flows back to today produces an estimated intrinsic value of about $36.44 per share. Compared with the recent share price of around $24.71, this suggests the stock is trading at roughly a 32.2% discount to the DCF estimate. Under this model, Elanco Animal Health appears to be priced below this assessment of its underlying cash flow value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Elanco Animal Health is undervalued by 32.2%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Elanco Animal Health Price vs Sales

For companies where profitability is limited or earnings are volatile, the P/S ratio is often a more useful cross check than P/E because it compares what investors are paying to the revenue the business is already generating. Higher expected growth and lower perceived risk usually justify a higher revenue multiple, while slower growth or higher risk tends to mean a lower, more conservative multiple is seen as fair.

Elanco Animal Health currently trades on a P/S ratio of 2.52x. This sits below both the Pharmaceuticals industry average of 5.70x and the peer group average of 4.09x. Simply Wall St’s Fair Ratio framework estimates what a company’s P/S multiple might reasonably be given factors such as its earnings growth profile, industry, profit margins, market value and key risks, rather than relying only on broad peer comparisons.

Because the Fair Ratio for Elanco Animal Health is 4.17x, which is higher than the current 2.52x P/S, the stock appears undervalued on this metric relative to that company specific benchmark.

Result: UNDERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Elanco Animal Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a clear story behind the numbers by linking your view on Elanco Animal Health’s products, margins and growth with a forecast and a Fair Value that you can easily compare to the current share price. All of this appears within the Community page where millions of investors share their work. These Narratives then update automatically when new earnings, guidance or news lands. One investor might build a more optimistic Elanco view around a Fair Value near US$32.00, while another might lean on a more cautious Fair Value closer to US$22.49. By seeing these side by side you can quickly decide which story best matches your own expectations for revenue, earnings and risk.

For Elanco Animal Health however we'll make it really easy for you with previews of two leading Elanco Animal Health Narratives:

Start with the bullish take if you think the new product cycle, margin work and balance sheet progress can support a higher valuation, or the more cautious take if you think execution risks and competition deserve a discount.

Fair Value in this narrative: US$29.79 per share

Implied discount versus that Fair Value at the recent US$24.71 share price: about 17.1% below the narrative Fair Value

Revenue growth assumption: 4.82% a year

• Analysts in this camp see Elanco’s divestments, such as the Aqua business, and new launches helping reduce debt and give the company more room to invest, with the aim of lifting net margins over time.
• The thesis leans on a pipeline that includes multiple potential blockbuster products, plus a broad pet and farm animal portfolio across regions, to support steady revenue growth and higher earnings.
• Key watchpoints are foreign exchange headwinds, higher operating expenses tied to launches and marketing, and how quickly products like Zenrelia and Credelio Quattro gain traction in veterinary channels.

Fair Value in this narrative: US$22.49 per share

Implied premium versus that Fair Value at the recent US$24.71 share price: about 9.9% above the narrative Fair Value

Revenue growth assumption: 5.03% a year

• The more cautious view highlights ongoing R&D and marketing spend for launches such as Credelio Quattro and Zenrelia, which lifts operating costs and may limit how much net margins can improve if base business growth is flat.
• Higher debt levels, potential generic competition and regulatory demands are seen as constraints on financial flexibility and pricing power, with customer consolidation and changing preferences adding further pressure.
• This camp still expects revenue and earnings growth, but treats the stock as closer to fairly valued around the low US$20s if execution on debt reduction, cost control and product uptake is less favourable than bullish expectations.

Do you think there's more to the story for Elanco Animal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.